SCHEMBL4085587

SCHEMBL4085587

Cc1cc(CC(N)=O)n(C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.42
DAO P14920 1/20 0.40
P2RX7 Q99572 1/20 0.38
FFAR1 O14842 1/20 0.38
LMNA P02545 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
KCNH2 Q12809 2/20 0.36
TSHR P16473 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GRIN2B Q13224 1/20 0.35
MPO P05164 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20353295 0.83 SMN1; SMN2 (0.43) SMN1; SMN2DAOP2RX7FFAR1LMNA
SCHEMBL2827976 0.83 LMNA (0.46) SMN1; SMN2DAOP2RX7FFAR1LMNA
SCHEMBL2828555 0.83 SMN1; SMN2 (0.38) HTTSMN1; SMN2DAOP2RX7FFAR1
SCHEMBL24159031 0.82 P2RX7 (0.47) HTTSMN1; SMN2DAOP2RX7FFAR1
SCHEMBL12492462 0.81 SMN1; SMN2 (0.42) SMN1; SMN2DAOP2RX7FFAR1LMNA
SCHEMBL2827324 0.81 KDM4E (0.51) HTTSMN1; SMN2DAOP2RX7FFAR1
SCHEMBL1030032 0.79 HTT (0.44) HTTLMNAKDM4EALDH1A1PKM
SCHEMBL24589257 0.79 SMN1; SMN2 (0.51) HTTSMN1; SMN2DAOP2RX7FFAR1
SCHEMBL24956529 0.79 HTT (0.37) HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL2824324 0.77 KDM4E (0.48) HTTSMN1; SMN2FFAR1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
EP-1861384-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS Sterix Limited (GB) 2007-12-05 EP disclosed
WO-2006100502-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS STERIX LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors HSD3B1, HSD3B2, HSD11B1 HTT 4393/4885SMN1; SMN2 4801/4885DAO 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.